Skip to main content
. Author manuscript; available in PMC: 2021 Sep 8.
Published in final edited form as: Pediatr Res. 2019 Oct 22;87(4):745–752. doi: 10.1038/s41390-019-0614-2

Table 4.

Application of preliminary clinical score to patients and controls

Clinical preliminary score Probable Autoinflammatory interferonopathies, n = 12 JIA, n = 6 JSLE, n = 4 DADA2, n = 5 JDM, n = 4
Skin manifestations 12/12 0/6 0/4 1/5 1/4
Vasculopathy 6/12 0/6 0/4 1/5 0/4
Lipodystrophy 2/12 0/6 0/4 0/5 0/4
Joint manifestations 5/12 0/6 0/4 0/5 2/4
Myositis 3/12 0/6 0/4 0/5 0/4
CNS manifestations 8/12 0/6 0/4 0/5 0/4
Pulmonary involvement 2/12 0/6 0/4 0/5 1/4
Leukopenia/lymphopenia with flares 4/12 0/6 4/4 1/5 0/4
Clinical score, median (min–max) 3 (3–5) 0 (0) 1 (0–1) 0 (0–1) 1 (0–2)

All items were scored as no (0) or yes (1)

CNS central nervous system, min–max minimum–maximum